In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.

The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...

Elahere showed superior efficacy over chemotherapy in progression-free survival, objective response rate, and overall survival in the MIRASOL trial. The treatment reduced the risk of tumor progression ...

Ovarian cancer mortality rates have declined, but disparities persist across age, race, and geographic regions. Older women, non-Hispanic White women, and those in the Northeast and Midwest have ...

Keytruda with paclitaxel, with or without Avastin, improved PFS and OS in PRROC patients, irrespective of PD-L1 status. The trial showed significant benefits in both CPS ≥1 and intention-to-treat ...

Investigators evaluated atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for patients with recurrent ovarian cancer.

Rising ovarian and uterine cancer rates are linked to high BMI, with disparities across sociodemographic index levels, particularly in low- and middle-SDI regions. Sarcopenia is prevalent in ...

Combing data collected on thousands of California ovarian cancer patients, UC Davis researchers have determined that almost one-third survived at least 10 years after diagnosis. The unprecedented ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Four leading ovarian cancer research charities from four countries are funding a new AI Accelerator Grant in partnership with Microsoft's AI for Good Lab to supercharge the next cancer research ...